Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CPT2 | P23786 | 1/20 | 0.47 |
| ▸ | CPT1A | P50416 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 14/20 | 0.47 |
| ▸ | MAOB | P27338 | 14/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | CDC25C | P30307 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308254 | 1.00 | GAA (0.50) | GAAKDM4ECPT2CPT1AMAOA | |
| SCHEMBL2304431 | 0.85 | CPT2 (0.51) | CPT2CPT1AMAOBBAZ2A | |
| SCHEMBL2304427 | 0.85 | CPT2 (0.51) | CPT2CPT1AMAOBBAZ2A | |
| SCHEMBL2308134 | 0.84 | ALDH1A1 (0.48) | GAAKDM4ECPT1AMAOAMAOB | |
| SCHEMBL2307050 | 0.84 | BAZ2A (0.47) | GAAKDM4ECPT1ASMN1; SMN2BAZ2A | |
| SCHEMBL2307046 | 0.84 | BAZ2A (0.47) | GAAKDM4ECPT1ASMN1; SMN2BAZ2A | |
| SCHEMBL2308127 | 0.84 | ALDH1A1 (0.48) | GAAKDM4ECPT1AMAOAMAOB | |
| SCHEMBL2308432 | 0.83 | HPGDS (0.49) | KDM4ECPT1AMAOAMAOBSMN1; SMN2 | |
| SCHEMBL2308428 | 0.83 | BAZ2A (0.46) | KDM4ECPT2CPT1ASMN1; SMN2BAZ2A | |
| SCHEMBL2308438 | 0.83 | HPGDS (0.49) | KDM4ECPT1AMAOAMAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039487-B2 | Piperidine-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2155738-B1 | PIPERIDINE-AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | CPT1A, CPT1B, CPT2 | GAA 477/4885KDM4E 1573/4885CPT2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.